Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis
Abstract Background Bladder cancer (BC) is a common malignancy neoplasm diagnosed in advanced stages in most cases. It is crucial to screen ideal biomarkers and construct a more accurate prognostic model than conventional clinical parameters. The aim of this research was to develop and validate an m...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-07-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08611-z |
id |
doaj-7fde5864285c4a688f995f487bcc635f |
---|---|
record_format |
Article |
spelling |
doaj-7fde5864285c4a688f995f487bcc635f2021-08-01T11:32:58ZengBMCBMC Cancer1471-24072021-07-0121111610.1186/s12885-021-08611-zConstruction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysisJianpeng Li0Jinlong Cao1Pan Li2Zhiqiang Yao3Ran Deng4Lijun Ying5Junqiang Tian6Department of Urology, The Second Hospital of Lanzhou UniversityDepartment of Urology, The Second Hospital of Lanzhou UniversityDepartment of Urology, The Second Hospital of Lanzhou UniversityDepartment of Urology, The Second Hospital of Lanzhou UniversityDepartment of Urology, The Second Hospital of Lanzhou UniversityDepartment of Urology, The Second Hospital of Lanzhou UniversityDepartment of Urology, The Second Hospital of Lanzhou UniversityAbstract Background Bladder cancer (BC) is a common malignancy neoplasm diagnosed in advanced stages in most cases. It is crucial to screen ideal biomarkers and construct a more accurate prognostic model than conventional clinical parameters. The aim of this research was to develop and validate an mRNA-based signature for predicting the prognosis of patients with bladder cancer. Methods The RNA-seq data was downloaded from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were screened in three datasets, and prognostic genes were identified from the training set of TCGA dataset. The common genes between DEGs and prognostic genes were narrowed down to six genes via Least Absolute Shrinkage and Selection Operator (LASSO) regression, and stepwise multivariate Cox regression. Then the gene-based risk score was calculated via Cox coefficient. Time-dependent receiver operating characteristic (ROC) and Kaplan-Meier (KM) survival analysis were used to assess the prognostic power of risk score. Multivariate Cox regression analysis was applied to construct a nomogram. Decision curve analysis (DCA), calibration curves, and time-dependent ROC were performed to assess the nomogram. Finally, functional enrichment of candidate genes was conducted to explore the potential biological pathways of candidate genes. Results SORBS2, GPC2, SETBP1, FGF11, APOL1, and H1–2 were screened to be correlated with the prognosis of BC patients. A nomogram was constructed based on the risk score, pathological stage, and age. Then, the calibration plots for the 1-, 3-, 5-year OS were predicted well in entire TCGA-BLCA patients. Decision curve analysis (DCA) indicated that the clinical value of the nomogram was higher than the stage model and TNM model in predicting overall survival analysis. The time-dependent ROC curves indicated that the nomogram had higher predictive accuracy than the stage model and risk score model. The AUC of nomogram time-dependent ROC was 0.763, 0.805, and 0.806 for 1-year, 3-year, and 5-year, respectively. Functional enrichment analysis of candidate genes suggested several pathways and mechanisms related to cancer. Conclusions In this research, we developed an mRNA-based signature that incorporated clinical prognostic parameters to predict BC patient prognosis well, which may provide a novel prognosis assessment tool for clinical practice and explore several potential novel biomarkers related to the prognosis of patients with BC.https://doi.org/10.1186/s12885-021-08611-zBladder cancer (BC)Differentially expressed genes (DEGs)Overall survival (OS)Risk scoreNomogramTCGA |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jianpeng Li Jinlong Cao Pan Li Zhiqiang Yao Ran Deng Lijun Ying Junqiang Tian |
spellingShingle |
Jianpeng Li Jinlong Cao Pan Li Zhiqiang Yao Ran Deng Lijun Ying Junqiang Tian Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis BMC Cancer Bladder cancer (BC) Differentially expressed genes (DEGs) Overall survival (OS) Risk score Nomogram TCGA |
author_facet |
Jianpeng Li Jinlong Cao Pan Li Zhiqiang Yao Ran Deng Lijun Ying Junqiang Tian |
author_sort |
Jianpeng Li |
title |
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis |
title_short |
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis |
title_full |
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis |
title_fullStr |
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis |
title_full_unstemmed |
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis |
title_sort |
construction of a novel mrna-signature prediction model for prognosis of bladder cancer based on a statistical analysis |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2021-07-01 |
description |
Abstract Background Bladder cancer (BC) is a common malignancy neoplasm diagnosed in advanced stages in most cases. It is crucial to screen ideal biomarkers and construct a more accurate prognostic model than conventional clinical parameters. The aim of this research was to develop and validate an mRNA-based signature for predicting the prognosis of patients with bladder cancer. Methods The RNA-seq data was downloaded from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were screened in three datasets, and prognostic genes were identified from the training set of TCGA dataset. The common genes between DEGs and prognostic genes were narrowed down to six genes via Least Absolute Shrinkage and Selection Operator (LASSO) regression, and stepwise multivariate Cox regression. Then the gene-based risk score was calculated via Cox coefficient. Time-dependent receiver operating characteristic (ROC) and Kaplan-Meier (KM) survival analysis were used to assess the prognostic power of risk score. Multivariate Cox regression analysis was applied to construct a nomogram. Decision curve analysis (DCA), calibration curves, and time-dependent ROC were performed to assess the nomogram. Finally, functional enrichment of candidate genes was conducted to explore the potential biological pathways of candidate genes. Results SORBS2, GPC2, SETBP1, FGF11, APOL1, and H1–2 were screened to be correlated with the prognosis of BC patients. A nomogram was constructed based on the risk score, pathological stage, and age. Then, the calibration plots for the 1-, 3-, 5-year OS were predicted well in entire TCGA-BLCA patients. Decision curve analysis (DCA) indicated that the clinical value of the nomogram was higher than the stage model and TNM model in predicting overall survival analysis. The time-dependent ROC curves indicated that the nomogram had higher predictive accuracy than the stage model and risk score model. The AUC of nomogram time-dependent ROC was 0.763, 0.805, and 0.806 for 1-year, 3-year, and 5-year, respectively. Functional enrichment analysis of candidate genes suggested several pathways and mechanisms related to cancer. Conclusions In this research, we developed an mRNA-based signature that incorporated clinical prognostic parameters to predict BC patient prognosis well, which may provide a novel prognosis assessment tool for clinical practice and explore several potential novel biomarkers related to the prognosis of patients with BC. |
topic |
Bladder cancer (BC) Differentially expressed genes (DEGs) Overall survival (OS) Risk score Nomogram TCGA |
url |
https://doi.org/10.1186/s12885-021-08611-z |
work_keys_str_mv |
AT jianpengli constructionofanovelmrnasignaturepredictionmodelforprognosisofbladdercancerbasedonastatisticalanalysis AT jinlongcao constructionofanovelmrnasignaturepredictionmodelforprognosisofbladdercancerbasedonastatisticalanalysis AT panli constructionofanovelmrnasignaturepredictionmodelforprognosisofbladdercancerbasedonastatisticalanalysis AT zhiqiangyao constructionofanovelmrnasignaturepredictionmodelforprognosisofbladdercancerbasedonastatisticalanalysis AT randeng constructionofanovelmrnasignaturepredictionmodelforprognosisofbladdercancerbasedonastatisticalanalysis AT lijunying constructionofanovelmrnasignaturepredictionmodelforprognosisofbladdercancerbasedonastatisticalanalysis AT junqiangtian constructionofanovelmrnasignaturepredictionmodelforprognosisofbladdercancerbasedonastatisticalanalysis |
_version_ |
1721245786535100416 |